結腸癌における遺伝子変異状態によるがん薬代謝と抵抗の調節におけるオートファジーとPXRクロスストーク
関連する実験動画
Updated: Sep 10, 2025
Evangelos Koustas1,2, Panagiotis Sarantis2,3, Eleni-Myrto Trifylli4
1Oncology Department, General Hospital Evangelismos, Ipsilantou 45-47, 106 76 Athens, Greece.
Genes
|August 28, 2025
まとめ
オートファギは,妊娠中のX受容体 (PXR) の核転移を促進することによって,リノテカンの耐性を持つ大腸がん (CRC) を促進する. 自殺抑制はアポトーシスを強化し,CRC治療の潜在的な治療戦略を提供します.
科学分野:
- 腫瘍学
- 分子生物学
- 細胞生物学
背景:
- 結腸直腸がん (CRC) は,世界的に主要な悪性腫瘍です.
- 化学療法,特にイリノテカンに対する耐性は,CRC治療における大きな課題です.
- Pregnane X受容体 (PXR) とオートファギーは,化学抵抗と腫瘍の進行に関与しています.
研究 の 目的:
- 大腸がんにおけるイリノテカンの反応におけるmtKRAS依存のオートファジーとPXR発現の役割を調査する.
- オートファジー,PXR,およびイリノテカンの耐性との相互作用を明らかにする.
主な方法:
- 大腸がん細胞系は,イリノテカンと特定の阻害剤 (3- メチラデニン,ヒドロキシクロロキン,PI-103) で治療された.
- 活性のMTT,タンパク質発現のウェスタンブロット,PXRノックダウンのsiRNA,およびオートファギーのコンフォカル顕微鏡検査を含む.
- 研究は,タンパク質の定量化,遺伝子ノックダウン,サブセルラー局所化に焦点を当てて,オートファジーとアポトーシスの経路を分析した.
主要な成果:
- PXRのノックダウンは,オートファギーのレベルに影響を及ぼさなかったが,オートファギーの増加にもかかわらず,アポプトシス細胞死が増加した.
- 末期オートファギーの抑制により,PXRの発現が低下した.
- PI3K/ AKT/ mTORの抑制による自己消化誘発は,PXR発現を増加させた.
結論:
- オートファギーはPXR核転位を促進し,大腸がんにおけるイリノテカンの耐性を促進する.
- イリノテカンの耐性を克服するための有効な戦略である.
- この研究は,化学抵抗におけるオートファジーとPXRを結びつける新しいメカニズムを明らかにした.
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K


